INTRODUCTION {#s1}
============

Type 2 diabetes mellitus (T2DM) is a most common form of diabetes and is a major public health threat. It is estimated that the prevalence of T2DM in Chinese adult is about 11.6% \[[@R1]\]. T2DM appears to be increasing dramatically worldwide and the vital susceptibility factors contributing to this phenomenon are poor diet, obesity, and sedentary lifestyle \[[@R2], [@R3]\]. It is reported that both environmental risk factors and genetic components play important roles in the etiology and pathogenesis of T2DM.

T2DM, a complex metabolic disorder, is characterized by hyperglycemia with varying degrees of impaired insulin secretion and insulin resistance (IR) as a result of pancreatic β-cell dysfunction. Imbalance of energy metabolism is considered to be one of the important pathophysiological changes in T2DM, a disease which is also characterised by IR and hyperglycaemia. Accumulating evidence suggests that dysfunction of adipose tissue is contributing to the development of IR and T2DM. Obesity represents a situation of increased fat accumulation, whereas lipodystrophy indicates a situation in which the capacity of retaining lipid in adipocytes is impaired, and then prevents the accumulation of fat. In these situations, the ability of retaining lipid in adipose tissue is impaired, leading to lipotoxicity and consequently developing peripheral IR \[[@R4]\]. There is also evidence that saturated fatty acids are stored in non-adipocyte, decrease glucose conversion into glycogen, and result in cellular damage as a sequence of their lipotoxicity \[[@R5]\]. The lipotoxicity, in the β-cell, has also been considered to contribute to the etiology and pathology of T2DM \[[@R6]\].

In view of that, a number of studies highlighted the vital roles of energy metabolism relative genetics in determining T2DM risk; understanding single nucleotide polymorphisms (SNPs) correlated with T2DM susceptibility may be helpful for providing personalized diagnosis and prevention. The peroxisome proliferator-activated receptor gamma (PPARG), an important transcription factor, keep the balance of energy metabolism by promoting either energy dissipation or energy deposition \[[@R7]\]. Recent studies reported that *PPARG* gene was correlated with higher risk to diabetes \[[@R8]\] and the G allele of the rs1801282 C\>G polymorphism in *PPARG* gene was associated with T2DM rsk in a genome-wide association study (GWAS) \[[@R9]\] and has been replicated in some case-control studies; however, other studes found no association between this polymorphism and T2DM \[[@R10]--[@R12]\]. The peroxisome proliferator-activated receptor gamma co-activator 1 (PPARGC1) family (e.g. PPARGC1A, PPARGC1B) has been considered as a vital regulator of fatty acid oxidation, gluconeogenesis and adaptive thermogenesis \[[@R13]\]. Of late, several studies explored the association between *PPARGC1A* polymorphisms and risk of T2DM. Results of a pooled-analysis suggested that *PPARGC1A* rs8192678G\>A and rs2970847C\>T polymorphisms were associated with the increased risk of T2DM in the Indian population \[[@R14], [@R15]\]. However, in these studies, the number of eligible publications and included subjects was limited and the power might be insufficient. Previous study reported that *PPARGC1B* rs7732671G\>C and rs17572019G\>A variants were associated with the decreased risk of obesity \[[@R16]\]. Thus, they may alter the risk of T2DM. Therefore, in this study, we designed a hospital-based case-control study and selected *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms to assess the relationship between these SNPs and T2DM in an Eastern Chinese Han population using the SNPscan method.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

The anthropometric data, biochemistry characteristics, demographics and risk factors of all participants are listed in Table [1](#T1){ref-type="table"}. As shown in Table [1](#T1){ref-type="table"}, the mean ± SD of height, weight, BMI, FPG, total cholesterol, triglyceride, HDL-C and LDL-C levels was significantly higher in the T2DM group compared with non-diabetic normal controls (*P* \< 0.05). However, the mean ± SD of systolic pressure and diastolic pressure was not significant. Additionally, Table [1](#T1){ref-type="table"} showed that the present study was fully matched by age, gender, alcohol use and smoking status. The primary information of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms is showed in Table [2](#T2){ref-type="table"}. For these SNPs, the genotyping success rate was more than 99% in all samples. Minor allele frequency (MAF) and HWE in controls are summarized in Table [2](#T2){ref-type="table"}.

###### Distribution of selected demographic variables and risk factors in type 2 diabetes cases and controls

  Variable                     Cases (n=502)     Controls (n=782)   *P*^a^                    
  ---------------------------- ----------------- ------------------ ----------------- ------- -------------
  Age (years)                  65.20 (±9.51)                        64.67 (±9.80)             0.347
  Age (years)                                                                                 0.113
   \< 65                       227               45.22              389               49.74   
   ≥ 65                        275               54.78              393               50.26   
  Sex                                                                                         0.819
   Male                        332               66.14              522               66.75   
   Female                      170               33.86              260               33.25   
  Smoking status                                                                              0.264
   Never                       333               66.33              542               69.31   
   Ever                        169               33.67              240               30.69   
  Alcohol use                                                                                 0.263
   Never                       453               90.24              690               88.24   
   Ever                        49                9.76               92                11.76   
  Height (m)                   1.68 (±0.08)                         1.66 (±0.07)              **0.015**
  Weight (kg)                  67.63 (±11.42)                       64.62 (±9.96)             **\<0.001**
  BMI (kg/m^2^)                24.95 (±3.64)                        23.51 (±2.94)             **\<0.001**
  BMI (kg/m^2^)                                                                               **\<0.001**
   \< 24                       210                                  436                       
   ≥ 24                        292                                  346                       
  Systolic pressure (mmHg)     135.08 (±17.83)                      134.02 (±17.71)           0.297
  Diastolic pressure (mmHg)    79.79 (±10.35)                       80.06 (±10.02)            0.649
  FPG (mmol/L)                 8.08 (±2.76)                         5.13 (±0.49)              **\<0.001**
  Total cholesterol (mmol/L)   4.61 (±1.24)                         4.88 (±1.02)              **\<0.001**
  Triglyceride (mmol/L)        1.74 (±1.14)                         1.55 (±0.96)              0.001
  HDL-C (mmol/L)               1.13 (±0.37)                         1.30 (±0.37)              **\<0.001**
  LDL-C (mmol/L)               3.00 (±1.07)                         3.14 (±0.82)              0.010

^a^ Two-sided *x*^2^ test and student t test; Bold values are statistically significant (*P* \<0.05); BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

###### Primary information for *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms

  Genotyped SNPs                              *PPARG* rs1801282 C\>G   *PPARG* rs3856806 C\>T   *PPARGC1A* rs8192678 C\>T   *PPARGC1A* rs2970847 C\>T   *PPARGC1A* rs3736265 G\>A   *PPARGC1B* rs7732671 G\>C   *PPARGC1B* rs17572019 G\>A
  ------------------------------------------- ------------------------ ------------------------ --------------------------- --------------------------- --------------------------- --------------------------- ----------------------------
  Chromosome                                  3                        3                        4                           4                           4                           5                           5
  Function                                    missense                 coding-synonymous        missense                    coding-synonymous           missense                    missense                    missense
  Chr Pos (NCBI Build 37)                     12393125                 12475557                 23815662                    23815924                    23814707                    149212243                   149212471
  Regulome DB Score^a^                        ---                      2b                       6                           ---                         6                           5                           5
  MAF^b^ for Chinese in database              0.07                     0.25                     0.35                        0.28                        0.23                        0.09                        0.07
  MAF in our controls (n = 782)               0.05                     0.22                     0.44                        0.21                        0.16                        0.06                        0.06
  *P* value for HWE^c^ test in our controls   0.973                    0.381                    0.850                       0.281                       0.064                       0.693                       0.305
  Genotyping method                           SNPscan                  SNPscan                  SNPscan                     SNPscan                     SNPscan                     SNPscan                     SNPscan
  \% Genotyping value                         99.61%                   99.61%                   99.61%                      99.61%                      99.38%                      99.61%                      99.61%

^a^ <http://www.regulomedb.org/>;

^b^ MAF: minor allele frequency;

^c^ HWE: Hardy--Weinberg equilibrium;

Association of PPARG rs1801282 C\>G, PPARG rs3856806 C\>T, PPARGC1A rs8192678 C\>T, PPARGC1A rs2970847 C\>T, PPARGC1A rs3736265 G\>A, PPARGC1B rs7732671 G\>C and PPARGC1B rs17572019 G\>A polymorphisms with T2DM {#s2_2}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The genotype distributions of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms are listed in Table [3](#T3){ref-type="table"}. The genotype distributions of these polymorphisms in controls were suggested to be in HWE. In the analysis of *PPARGC1A* rs3736265 G\>A polymorphism, differences in the frequency distribution of the GA/AA genotypes compared with the GG genotype and GA genotype compared with the GG genotype between T2DM patients and non-diabetic controls were found \[GA+AA vs. GG: crude odds ratio (OR) = 0.76, 95% confidence interval (CI) = 0.59--0.99, *P* = 0.041 and GA vs. GG: crude OR = 0.76, 95% CI = 0.58--1.00, *P* = 0.049 (Table [3](#T3){ref-type="table"})\]. However, *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms was not associated with T2DM susceptibility (Table [3](#T3){ref-type="table"}). In two genetic models, logistic regression analysis demonstrated that *PPARGC1A* rs3736265 G\>A polymorphism was associated with a borderline statistically risk of T2DM. When the *PPARGC1A* rs3736265 GG genotypes were used as the reference group, the GA/AA and GA genotype was correlated with a borderline statistically decreased susceptibility of T2DM \[GA+AA vs. GG: adjusted OR = 0.77, 95% CI = 0.59--1.00, *P* = 0.050 and GA vs. GG: adjusted OR = 0.76, 95% CI = 0.58--1.00, *P* = 0.053 (Table [3](#T3){ref-type="table"})\].

###### Logistic regression analyses of associations between *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms and risk of type 2 diabetes

  Genotype                     Cases(n=502)   Controls(n=782)   Crude OR (95%CI)   *P*     Adjusted OR ^a^ (95%CI)   *P*                              
  ---------------------------- -------------- ----------------- ------------------ ------- ------------------------- ----------- -------------------- -------
  *PPARG* rs1801282 C\>G                                                                                                                              
  CC                           457            91.95             704                90.03   1.00                                  1.00                 
  CG                           40             8.05              76                 9.72    0.80 (0.54-1.20)          0.280       0.76(0.50-1.14)      0.179
  GG                           0              0                 2                  0.26    \-                        \-          \-                   \-
  GC+GG                        40             8.05              78                 9.98    0.79 (0.53-1.18)          0.247       0.75 (0.50-1.12)     0.164
  CC+GC                        497            100               780                99.75   1.00                                  1.00                 
  GG                           0              0                 2                  0.26    \-                        \-          \-                   \-
  G allele                     40             4.02              80                 5.12                                                               
  *PPARG* rs3856806 C\>T                                                                                                                              
  CC                           278            55.94             474                60.61   1.00                                  1.00                 
  CT                           196            39.44             275                35.17   1.19 (0.94-1.51)          0.140       1.17(0.92-1.48)      0.204
  TT                           23             4.63              33                 4.22    1.17 (0.67-2.03)          0.583       1.19 (0.68-2.08)     0.541
  CT+TT                        219            44.06             308                39.39   1.21 (0.97-1.52)          0.098       1.19 (0.94-1.50)     0.140
  CC+CT                        474            95.37             749                95.78   1.00                                  1.00                 
  TT                           23             4.63              33                 4.22    1.10 (064-1.90)           0.728       1.14 (0.65-1.97)     0.653
  T allele                     242            24.35             341                21.80                                                              
  *PPARGC1A* rs8192678 C\>T                                                                                                                           
  CC                           138            27.77             250                31.97   1.00                                  1.00                 
  CT                           251            50.50             382                48.85   1.15 (0.89-1.49)          0.296       1.12 (0.86-1.46)     0.402
  TT                           108            21.73             150                19.18   1.26 (0.91-1.74)          0.161       1.22 (0.88-1.69)     0.240
  CT+TT                        269            54.12             532                68.03   1.22 (0.96-1.57)          0.111       1.19 (0.93-1.1.53)   0.178
  CC+CT                        389            78.27             632                80.82   1.00                                  1.00                 
  TT                           108            21.73             150                19.18   1.17 (0.89-1.54)          0.269       1.15(0.87-1.52)      0.334
  T allele                     467            46.98             682                43.61                                                              
  *PPARGC1A* rs2970847 C\>T                                                                                                                           
  CC                           310            62.37             485                62.02   1.00                                  1.00                 
  CT                           160            32.19             268                34.27   0.92 (0.72-1.17)          0.495       0.93 (0.73-1.19)     0.582
  TT                           27             5.43              29                 3.71    1.43 (0.83-2.47)          0.194       1.50 (0.87-2.60)     0.148
  CT+TT                        187            37.63             297                37.98   0.99 (0.78-1.24)          0.899       1.00 (0.79-1.27)     0.979
  CC+CT                        470            94.57             753                96.29   1.00                                  1.00                 
  TT                           27             5.43              29                 3.71    1.49 (0.87-2.55)          0.144       1.55(0.90-2.68)      0.112
  T allele                     214            21.53             326                20.84                                                              
  *PPARGC1A* rs3736265 G\>A                                                                                                                           
  GG                           380            76.61             557                71.41   1.00                                                       
  GA                           103            20.77             196                25.13   **0.76(0.58-1.00)**       **0.049**   0.76(0.58-1.00)      0.053
  AA                           13             2.62              27                 3.46    0.70(0.36-1.37)           0.295       0.74(0.37-1.46)      0.378
  GA + AA                      116            23.39             223                28.59   **0.76(0.59-0.99)**       **0.041**   0.77(0.59-1.00)      0.050
  GG+GA                        483            97.38             753                96.54   1.00                                  1.00                 
  AA                           13             2.62              27                 3.46    0.75(0.38-1.47)           0.403       0.79(0.40-1.56)      0.494
  A allele                     129            13.00             250                15.98                                                              
  *PPARGC1B* rs7732671 G\>C                                                                                                                           
  GG                           435            87.53             698                89.26   1.00                                  1.00                 
  GC                           61             12.27             81                 10.36   1.20(0.84-1.70)           0.323       1.20(0.84-1.72)      0.314
  CC                           1              0.20              3                  0.38    0.53(0.06-5.10)           0.582       0.48(0.05-4.71)      0.527
  GC+CC                        62             12.47             84                 10.74   1.18(0.84-1.68)           0.342       1.19(0.83-1.69)      0.341
  GG+GC                        496            99.80             779                99.62   1.00                                  1.00                 
  CC                           1              0.20              3                  0.38    0.52(0.05-5.05)           0.576       0.47(0.05-4.66)      0.520
  C allele                     63             6.34              87                 5.56                                                               
  *PPARGC1B* rs17572019 G\>A                                                                                                                          
  GG                           435            87.53             698                89.26   1.00                                                       
  GA                           60             12.07             80                 10.23   1.19(0.83-1.70)           0.338       1.19(0.83-1.71)      0.338
  AA                           2              0.40              4                  0.51    0.79(0.15-4.35)           0.790       0.81(0.14-4.52)      0.808
  GA+AA                        62             12.47             84                 10.74   1.18(0.84-1.68)           0.343       1.19(0.83-1.69)      0.341
  GG+GA                        495            99.60             778                99.49   1.00                                                       
  AA                           2              0.40              4                  0.51    0.79(0.14-4.31)           0.781       0.80(0.14-4.49)      0.80
  A allele                     64             6.44              88                 5.63                                                               

^a^ Adjusted for age, sex, smoking status, alcohol use and BMI status.

Bold values are statistically significant (*P* \<0.05).

Association of PPARGC1A rs3736265 G\>A polymorphism with T2DM in Different Stratification Groups {#s2_3}
------------------------------------------------------------------------------------------------

Table [4](#T4){ref-type="table"} showed the genotype frequencies of *PPARGC1A* rs3736265 G\>A polymorphism in the stratified analysis based on age, gender, alcohol use, smoking status and BMI. In female group, after adjustment for age, alcohol use, smoking status and BMI by logistic regression analysis, the GA/AA and GA genotypes of *PPARGC1A* rs3736265 G\>A polymorphism were associated with a significantly decreased risk of T2DM compared with the GG genotype \[GA+AA vs. GG: adjusted OR = 0.46, 95% CI 0.28--0.74, P = 0.001 and GA vs. GG: adjusted OR = 0.45, 95% CI = 0.28--0.74, *P* = 0.002 (Table [4](#T4){ref-type="table"})\]. In \<65 years group, after adjustment for gender, alcohol use, smoking status and BMI by logistic regression analysis, the GA/AA and GA genotypes of *PPARGC1A* rs3736265 G\>A polymorphism were also associated with a significantly decreased risk of T2DM compared with the GG genotype \[GA+AA vs. GG: adjusted OR = 0.67, 95% CI 0.46--0.98, P = 0.038 and GA vs. GG: adjusted OR = 0.60, 95% CI = 0.40--0.90, *P* = 0.013 (Table [4](#T4){ref-type="table"})\]. However, in other groups, there was no correlation between *PPARGC1A* rs3736265 G\>A polymorphism and the risk of T2DM (*P* \> 0.05; Table [4](#T4){ref-type="table"}).

###### Stratified analyses between *PPARGC1A* rs3736265 G\>A polymorphism and type 2 diabetes risk by sex, age, smoking status, alcohol consumption and BMI

  Variable         (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                                                               
  ---------------- ------------------- ------------------------------ ------- --------- ------ --------------------------------- ------------------------------ --------------------------------- ------------------------------
  Sex                                                                                                                                                                                             
  Male             244/383             74/116                         11/21   85/137    1.00   0.99 (0.71-1.39);*P*: 0.952       0.86 (0.40-1.84);*P*: 0.705    0.98 (0.71-1.35);*P*: 0.886       0.87 (0.41-1.85);*P*: 0.713
  Female           136/174             29/80                          2/6     31/86     1.00   **0.45 (0.28-0.74);*P*: 0.002**   0.35 (0.07-1.79);*P*: 0.206    **0.46 (0.28-0.74);*P*: 0.001**   0.42 (0.08-2.15);*P*: 0.298
  Age (years)                                                                                                                                                                                     
  \<65             169/264             46/112                         9/11    55/123    1.00   **0.60 (0.40-0.90);*P*: 0.013**   1.28 (0.51-3.24);*P*: 0.596    **0.67 (0.46-0.98);*P*: 0.038**   1.43 (0.57-3.60);*P*: 0.442
  ≥65              211/293             57/84                          4/16    61/100    1.00   0.96 (0.65-1.41);*P*: 0.822       0.33 (0.11-1.03);*P*: 0.055    0.87 (0.60-1.26);*P*: 0.450       0.34 (0.11-1.04);*P*: 0.058
  Smoking status                                                                                                                                                                                  
  Never            251/386             69/137                         10/19   79/156    1.00   0.77 (0.55-1.07);*P*: 0.115       0.79 (0.36-1.75);*P*: 0.560    0.78 (0.57-1.07);*P*: 0.121       0.85 (0.38-1.86);*P*: 0.677
  Ever             129/171             34/59                          3/8     37/67     1.00   0.70 (0.43-1.16);*P*: 0.163       0.56 (0.14-2.22);*P*: 0.409    0.69 (0.43-1.12);*P*: 0.132       0.61 (0.16-2.42);*P*: 0.484
  Alcohol use                                                                                                                                                                                     
  Never            345/490             94/175                         9/24    103/199   1.00   0.76 (0.57-1.01);*P*: 0.061       0.53 (0.24-1.17);*P*: 0.118    0.74 (0.56-0.98);*P*: 0.035       0.57 (0.26-1.26);*P*: 0.165
  Ever             35/67               9/21                           4/3     13/24     1.00   0.80 (0.33-1.94);*P*: 0.620       2.28 (0.46-11.31);*P*: 0.313   0.99 (0.44-2.21);*P*: 0.976       2.37 (0.48-11.60);*P*: 0.288
  BMI (kg/m^2^)                                                                                                                                                                                   
  \<24             157/314             45/105                         6/15    51/120    1.00   0.85 (0.57-1.26);*P*: 0.418       0.84 (0.32-2.21);*P*: 0.722    0.86 (0.59-1.26);*P*: 0.428       0.88 (0.33-2.30);*P*: 0.787
  ≥24              224/243             58/91                          7/12    65/103    1.00   0.69 (0.47-1.01);*P*: 0.054       0.70 (0.27-1.82);*P*: 0.460    0.70 (0.49-1.00);*P*: 0.053       2.37 (0.29-1.98);*P*: 0.576

^a^ The genotyping was successful in 502 (98.80%) type 2 diabetes cases, and 782 (99.74%) controls for *PPARGC1A* rs3736265 G\>A;

^b^ Adjusted for age, sex, smoking status, alcohol use and BMI (besides stratified factors accordingly) in a logistic regression model;

Bold values are statistically significant (*P* \<0.05)

SNP haplotypes {#s2_4}
--------------

Using an expectation-maximization algorithm software \[SHESIS program (Bio-X Inc., Shanghai, China, <http://analysis.bio-x.cn/myAnalysis.php>)\] \[[@R17]\], we constructed thirteen haplotypes (Table [5](#T5){ref-type="table"}). Haplotype comparison analysis indicated that CTTCGGG and CTCTGGG haplotypes with the order of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms in gene position significantly increased the risk of T2DM (OR = 1.39, 95% CI = 1.01--1.90; *P* = 0.041; and OR = 1.83, 95% CI = 1.22--2.75; *P* = 0.003, respectively). However, CCCCACA haplotype with the same order of polymorphisms in gene position conferred a decreased risk to T2DM (*P* = 0.008).

###### *PPARG-PPARGC1A-PPARGC1B* haplotype frequencies (%) in cases and controls and risk of type 2 diabetes

  Haplotypes      Cases (n=1004)   Controls (n=1564)   Crude OR (95% CI)     *P*
  --------------- ---------------- ------------------- --------------------- -----------
  C C T C G G G   329(33.13)       507(32.50)          1.00                  
  C C C T G G G   133(13.39)       244(15.64)          0.84(0.65-1.08)       0.176
  C C C C G G G   129(13.00)       200(12.82)          0.99(0.77-1.29)       0.964
  C C C C A G G   98(9.82)         188(12.05)          0.80(0.61-1.06)       0.126
  C T T C G G G   91(9.16)         101(6.47)           **1.39(1.01-1.90)**   **0.041**
  C T C T G G G   57(5.74)         48(3.08)            **1.83(1.22-2.75)**   **0.003**
  C T C C G G G   32(3.22)         72(4.62)            0.68(0.44-1.06)       0.090
  C C T C G C A   31(3.12)         32(2.05)            1.49(0.89-2.49)       0.124
  C T C C A G G   24(2.42)         40(2.56)            0.92(0.55-1.56)       0.770
  G T T C G G G   15(1.51)         27(1.73)            0.86(0.45-1.63)       0.637
  C C C C G C A   13(1.31)         16(1.03)            1.25(0.59-2.64)       0.553
  G T C T G G G   11(1.11)         15(0.96)            1.13(0.51-2.49)       0.762
  C C C C A C A   0 (0)            10(0.64)            \-                    **0.008**
  Others          30(3.02)         60(3.85)            0.77(.49-1.22)        0.265

With the order of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms in gene position. Bold values are statistically significant (*P* \< 0.05).

Association between PPARGC1A rs3736265 G\>A polymorphism and biochemistry characteristics {#s2_5}
-----------------------------------------------------------------------------------------

As pharmacotherapy for T2DM might affect biochemistry characteristics, in this stage, only non-diabetic controls were enrolled. We evaluated the association of *PPARGC1A* rs3736265 G\>A polymorphism with biochemistry characteristics using Student\'s t-test. As shown in Table [6](#T6){ref-type="table"}, there was a significant correlation of *PPARGC1A* rs3736265 G\>A polymorphism with FPG. When the FPG level of *PPARGC1A* rs3736265 GG genotype was used as the reference group, FPG level of the GA/AA and GA genotypes significantly decreased \[GA+AA vs. GG: *P* = 0.009 and GA vs. GG: *P* = 0.002 (Table [6](#T6){ref-type="table"})\]. We also found that *PPARGC1A* rs3736265 G\>A polymorphism had an association with Triglyceride. When the triglyceride level of *PPARGC1A* rs3736265 GG genotype was used as the reference group, triglyceride level of the AA genotype significantly increased (AA vs. GG: *P* = 0.014, Table [6](#T6){ref-type="table"}). When the triglyceride level of *PPARGC1A* rs3736265 GG/GA genotypes was used as the reference group, triglyceride level of the AA genotype also significantly increased (AA vs. GG/GA: *P* = 0.017, Table [6](#T6){ref-type="table"}).

###### Associations of the *PPARGC1A* rs3736265 G\>A genetic variants with biochemistry characteristics among control participants

  Genotype   Controls (n=782)   FPG (mmol/L)   *P*             Total cholesterol (mmol/L)   *P*         Triglyceride (mmol/L)   *P*             HDL-C (mmol/L)   *P*         LDL-C (mmol/L)   *P*         
  ---------- ------------------ -------------- --------------- ---------------------------- ----------- ----------------------- --------------- ---------------- ----------- ---------------- ----------- -------
  GG         557                71.41          5.16±0.47       1.0                          4.87±1.02   1.0                     1.52±0.93       1.0              1.29±0.35   1.0              3.14±0.82   1.0
  GA         196                25.13          **5.04±0.50**   **0.002**                    4.88±1.00   0.878                   1.57±0.97       0.507            1.33±0.39   0.238            3.11±0.79   0.704
  AA         27                 3.46           5.21±0.66       0.601                        5.10±1.22   0.249                   **1.97±0.95**   **0.014**        1.27±0.46   0.695            3.34±0.92   0.220
  GA + AA    223                28.59          **5.06±0.53**   **0.009**                    4.91±1.03   0.624                   1.62±0.97       0.179            1.32±0.40   0.337            3.14±0.81   0.980
  GG+GA      753                96.54          5.13±0.48       1.0                          4.87±1.01   1.0                     1.53±0.94       1.0              1.30±0.36   1.0              3.13±0.81   1.0
  AA         27                 3.46           5.21±0.66       0.395                        5.10±1.22   0.249                   **1.97±0.95**   **0.017**        1.27±0.46   0.606            3.34±0.92   0.197

FPG: fasting plasma glucose;

HDL-C, high-density lipoprotein cholesterol;

LDL-C, low-density lipoprotein cholesterol;

Bold values are statistically significant (*P* \<0.05)

DISCUSSION {#s3}
==========

T2DM is the most prevalent metabolic diseases worldwide, and it is multi-factorial **disorder that results from the interaction of individual\'s genetic background with environmental factor**. Recently, exploration of susceptibility variants has become an important approach to study the etiology of T2DM. Recent studies demonstrated that susceptibility of T2DM could be influenced by variants in some energy balance and lipid /glucose metabolism genes \[[@R18], [@R19]\]. We chose *PPARG*, *PPARGC1A*, *PPARGC1B* genes for their impact on glucose metabolism and the biological plausibility of a role in the development of IR \[[@R20], [@R21]\]. Using a case-control study approach, we investigated relationships of *PPARG*, *PPARGC1A*, *PPARGC1B* polymorphisms with T2DM. In addition, we studied the association between validated SNP and biochemistry characteristics. In this study, we identified that *PPARGC1A* rs3736265 G\>A polymorphism was associated with the decreased risk of T2DM. We also found *PPARGC1A* rs3736265 A allele might modulate the level of FPG and serum triglyceride.

*PPARG* rs1801282 C\>G polymorphism, a SNP in exon B, encodes a proline (Pro) to alanine (Ala) substitution at amino acid residue \[[@R22]\]. A previous study reported this missense substitution (Pro→Ala) might decrease transcriptional activation of *PPARG* gene *in vitro* \[[@R23]\]. The other important SNP in *PPARG* gene, rs3856806 C\>T polymorphism, is consistently associated with higher BMI, whilst *PPARG* rs1801282 C\>G polymorphism is consistently associated with a lower BMI \[[@R24]\]. *PPARG* rs1801282 C\>G and rs3856806 C\>T polymorphisms may affect the balance of energy metabolism and cell differentiation, and then presumably alter the susceptibility of T2DM. In this study, as shown in Table [3](#T3){ref-type="table"}, *PPARG* rs1801282 C\>G polymorphism might not confer the susceptibility to T2DM, which did not agree with results of the previous meta-analysis \[[@R25]\]. However, we found that only three small sample size studies with 1099 T2DM cases and 985 non-diabetic controls were included in that analysis \[[@R25]\]. The evidence might be limited. As for *PPARG* rs3856806 C\>T polymorphism, *Du et al*. \[[@R26]\] and *Liu et al*. \[[@R27]\] found that this SNP was associated with T2DM in a Chinese population. While *Cho et al*. \[[@R28]\] reported a negative result in cases with gestational diabetes mellitus in the Korean population, which was similar to our results. Therefore, whether the C→T transition of rs3856806 polymorphism in *PPARG* gene does change biological activity of PPARG protein are needed to be further explored.

PPARGC1A, a transcriptional co-activator of PPARG, regulates transcription in adipogenesis, oxidative metabolism and adaptive thermogenesis relative genes \[[@R29]\]. Recently, some functional studies reported that PPARGC1A also control the restoration of insulin-sensitive glucose transporter (Glucose transporter type 4) gene expression in muscle cells \[[@R30]\], gluconeogenesis in liver and as a central target of the hepatic insulin-cAMP axis \[[@R31]\]. Moreover, in muscle, decreased expression of PPARGC1A was observed in diabetes cases and even in non-diabetic individuals with a family history of diabetes \[[@R32]\]. Several epidemiological investigations have explored the effects of *PPARGC1A* rs8192678G\>A (Gly482Ser) and *PPARGC1A* rs2970847 C\>T (Thr394Thr) in exon 8 and *PPARGC1A* rs3736265 G\>A (Thr612Met) in exon 9 on the development of T2DM; however, the relationships have not been consistently replicated. For *PPARGC1A* rs8192678G\>A polymorphism, results of some meta-analysis attained consistent findings that this SNP is associated with the increased susceptibility to T2DM in overall populations \[[@R14], [@R15]\]. While in a subgroup analysis, this association between *PPARGC1A* rs8192678G\>A polymorphism and T2DM was not observed in east Asians \[[@R14]\], which is analogous to our findings. Previous study suggested that *PPARGC1A* rs3736265 G\>A polymorphism was associated with the decreased risk of T2DM in a Danish population, and the *PPARGC1A* rs3736265A allele might be a protective factor in T2DM \[[@R33]\]. However, *Kim et al*. reported that *PPARGC1A* rs3736265 G\>A polymorphism was not associated with the risk of T2DM in the Korean population \[[@R34]\]. In this study, we also focused on the association between *PPARGC1A* rs3736265 G\>A polymorphism and risk of T2DM. We identified that GA/AA and GA genotype of *PPARGC1A* rs3736265 G\>A polymorphism was correlated with a borderline statistically decreased susceptibility of T2DM. In subsroup analyses, we found that *PPARGC1A* rs3736265 G\>A polymorphism was associated with decreased risk of T2DM in \<65 years and female subgroups. As susceptibility SNP for T2DM might affect biochemistry characteristics, we also evaluated the association of *PPARGC1A* rs3736265 G\>A polymorphism with biochemistry characteristics. Results of our studies indicated that *PPARGC1A* rs3736265 G\>A polymorphism was associated with the decreased level of FPG, while it might increase the level of serum triglyceride. The variants of *PPARGC1A* rs3736265 G\>A polymorphism decrease the level of FPG, then they might be a protective factor for the development of T2DM. These associations between *PPARGC1A* rs3736265 G\>A polymorphism and biochemistry characteristics were consistent with the results of the present case-control study. However, given *PPARGC1A* rs3736265 G\>A polymorphism might have opposite effects on FPG and the level of triglyceride, function of this SNP should be further explored.

A number of studies have highlighted that PPARGC1B plays an important role in regulating energy metabolism including fatty acid oxidation, thermogenesis, gluconeogenesis and mitochondrial biogenesis \[[@R13], [@R31], [@R35], [@R36]\]. The human *PPARGC1B* gene, encoding the PPARGC1B protein, locates on chromosome 5q32, a relative area that suggests linkage to T2DM \[[@R24]\]. The *PPARGC1B* rs7732671G\>C and rs17572019G\>A variants were in almost complete linkage disequilibrium in Caucasians (R^2^ = 0.958) and they were associated with the decreased risk of obesity \[[@R16]\]. A recent GWAS study demonstrated that *PPARGC1B* rs7732671G\>C and rs17572019G\>A polymorphisms were not associated with T2DM risk \[[@R12]\]. In this study, the distribution of genotype frequencies of *PPARGC1B* rs7732671G\>C and rs17572019G\>A polymorphisms was not significantly different between T2DM cases and the controls. The findings were consistent with the previous GWAS studies mentioned above.

Because *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms may be not inherited randomly, but as construction of alleles in this study, we harnessed an online program to analyze inherited patterns of the seven SNPs. We found the frequency of CTTCGGG and CTCTGGG haplotypes with the order of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms in gene position was significantly increased in T2DM patients. However, CCCCACA haplotype with the same order of polymorphisms may decreased the risk of T2DM. We first reported the association of combined *PPARG*, *PPARGC1A* and *PPARGC1B* haplotypes with T2DM susceptibility.

Using an online Power and Sample Size Calculator (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>), the power of the present study was evaluated (α=0.05). For *PPARGC1A* rs3736265 G\>A polymorphism, the power was 0.469 in additive model and 0.508 in dominant model among overall T2DM group, 0.919 in additive model and 0.920 in dominant model among female subgroup, and 0.721 in additive model and 0.558 in dominant model among \<65 years subgroup.

Like all epidemiological case--control studies, some limitations should be taken into account. Firstly, our study was that it was designed as a hospital-based study. All T2DM cases and non-diabetic controls were recruited from two hospitals which located in Eastern China. Although, in our study, the MAF in controls was very similar to the MAF of Chinese in the database (Table [2](#T2){ref-type="table"}), the selection bias might have occurred. Secondly, we only selected seven important SNPs in *PPARG* and PPARGC1 family gene, which might not give an extensive view of the genetic susceptibility in *PPARG*, *PPARGC1A* and *PPARGC1B*. Thirdly, since significant correlation was manly found in subgroups of patients after a stratified analysis, the power of study might be limited. In the future, further studies with large sample sizes and detailed gene-environmental data are need to confirm or refute these results.

In conclusion, to the best of our knowledge, this is the first investigation about the possible correlation between *PPARGC1A* rs3736265 G\>A polymorphism and biochemistry characteristics. Our findings suggest that variants of *PPARGC1A* rs3736265 G\>A polymorphism decrease the level of FPG, improving the expectation of study in individual\'s prevention strategies to T2DM.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

A total of 1,284 subjects from Eastern Chinese Han population were enrolled for this case-control study. There were 502 T2DM patients and 784 non-diabetic controls. Our study conforms to the items of the Declaration of Helsinki, and was approved by Jiangsu University (Zhenjiang, China) and Fujian Medical University Ethics Committee (Fuzhou, China). T2DM cases were selected from the department of endocrine at the Affiliated People\'s Hospital of Jiangsu University and the Affiliated Union Hospital of Fujian Medical University, and the controls were recruited from Health Check Centers at these hospitals. All participants provided written informed consent. All subjects were recruited between October 2014 and May 2016 consecutively. Demographic variables and risk factors of all subjects were collected by two experienced doctors. Anthropometric measurements (e.g. systolic blood pressure, diastolic blood pressure, weight and height) were tested using standard techniques. Body mass index (BMI) was assessed as weight (kilograms) divided by height (meters) squared. Serum triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL-C), high-density lipoprotein cholesterol (LDL-C), and fasting plasma glucose (FPG) were also measured. In addition, according to the criterion for overweight and obesity, a BMI of 24 was used as the cut-off point in Chinese adults \[[@R37], [@R38]\]. The information is listed in Table [1](#T1){ref-type="table"}. All experimental protocol was conducted in accordance with the approved guidelines.

The World Health Organization 1999 guidelines of T2DM were used as the criteria for diagnosis \[[@R18]\]. For the eligible controls, the following criteria were used: no history of T2DM, postprandial plasma glucose (PPG) \< 7.8 mmol/L and normoglycemia \[FPG \< 6.1 mmol/l)\] \[[@R19]\].

DNA extraction and genotyping {#s4_2}
-----------------------------

Samples of peripheral blood were collected with ethylenediamine tetraacetic acid (EDTA) anticoagulant vacutainer tubes (BD Franklin Lakes NJ, USA). Blood samples were stored at -20°C. Genomic DNA was extracted from lymphocytes using the Promega Genomic DNA Purification Kit (Promega, Madison, USA). The genomic DNA obtained was frozen at -80°C for SNP analysis. Genotyping of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms was carried out using the SNPscan^TM^ genotyping assay (Gnensky Biotechologies Inc., Shanghai, China). The success rate of all genotyping was \> 99% (Table [2](#T2){ref-type="table"}). The genotypes of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms were confirmed by the same DNA genotyping method in fifty-two (4%) randomly selected samples.

Statistical analysis {#s4_3}
--------------------

All statistical analyses were performed in SAS 9.4 software (SAS Institute, Cary, NC). The data of continuous variables are expressed as the mean ± standard deviation (SD). Student\'s t-test was harnessed to determine the differences for normally distributed continuous variables between T2DM cases and controls. Chi-square test (*χ*^2^) was conducted to measure the differences for categorical variables (e.g. genotypes, sex, age, smoking status, alcohol use and BMI). We used an internet-based calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) to measure the Hardy--Weinberg equilibrium (HWE) in controls with the genotype frequencies of *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms. The associations between *PPARG* rs1801282 C\>G, *PPARG* rs3856806 C\>T, *PPARGC1A* rs8192678 C\>T, *PPARGC1A* rs2970847 C\>T, *PPARGC1A* rs3736265 G\>A, *PPARGC1B* rs7732671 G\>C and *PPARGC1B* rs17572019 G\>A polymorphisms and risk of T2DM were assessed by crude ORs and adjusted ORs when it was appropriate. SHESIS software (Bio-X Inc., Shanghai, China, <http://analysis.bio-x.cn/myAnalysis.php>) was used for construction of haplotypes \[[@R17]\]. A *P* \< 0.05 (two-tailed) was considered as the criterion of statistical significance.
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